15α,16α-dimethylene-4-androsten-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 15α,16α-dimethylene-4-androsten-3-one
• 英文别名: 15β,16β-dimethylene-4-androsten-3-one；15β,16β-bismethylene-androst-4-en-3-one；(8R,9S,10R,13R,14S)-10,13-dimethyl-15,16-dimethylidene-1,2,6,7,8,9,11,12,14,17-decahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₂₁H₂₈O
• 分子量: 296.453
• InChiKey: AGLWPINZFNODOQ-IFLJBQAJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  15α,16α-dimethylene-4-androsten-3-one 、 2,3-二氯-5,6-二氰基-1,4-苯醌 以 1,4-二氧六环 为溶剂， 生成 15β,16β-dimethylene-1,4-androstadien-3-one
  参考文献：
  名称：

  6.beta.,7.beta.;15,16-Dimethylene-1,4-androstadien-3-ones, their

  摘要：

  式为##STR1##的化合物，其中15,16-亚甲基团位于α-或β-位置，E为##STR2##，可用作利尿剂。

  公开号：

  US04291029A1

文献信息

• Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
  申请人：G.D. Searle & Company

  公开号：US20030055274A1

  公开（公告）日：2003-03-20

  Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of formula (I) wherein: —A—A— represents the group —CHR 4 —CHR 5 — or —CR 4 ═CR 5 —, R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halo, hydroxy, lower alkyl, lower alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, cyano, aryloxy; R 1 represents an alpha-oriented lower alkoxycarbonyl or hydroxyalkyl radical; —B—B— represents the group —CHR 6 —CHR 7 — or an alpha- or beta-oriented group (III), where R 6 and R 7 are independently selected from the group consisting of hydrogen, halo, lower alkoxy, acyl, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, alkyl, alkoxycarbonyl, acyloxyalkyl, cyano and aryloxy; and R 8 and R 9 are independently selected from the group consisting of hydrogen, hydroxy, halo, lower alkoxy, acyl, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, alkyl, alkoxycarbonyl, acyloxyalkyl, cyano and aryloxy, or R 8 and R 9 together comprise a carbocyclic or heterocyclic ring structure, or R 8 or R 9 together with R 6 or R 7 comprise a carbocyclic or heterocyclic ring structure fused to the pentacyclic D ring. 1

  提供了多种新颖的反应方案、新颖的工艺步骤和新颖的中间体，用于合成环氧甲基孟酮和其他式（I）化合物，其中：—A—A—代表基团—CHR4—CHR5—或—CR4═CR5—，R3、R4和R5独立地选自氢、卤素、羟基、低碳基、低烷氧基、羟基烷基、烷氧基烷基、羟基羰基、氰基、芳氧基的群；R1代表α定向的低碳基羧酸酯或羟基烷基基团；—B—B—代表基团—CHR6—CHR7—或α-或β定向的基团（III），其中R6和R7独立地选自氢、卤素、低烷氧基、酰基、羟基烷基、烷氧基烷基、羟基羰基、烷基、烷氧基羧酸酯、酰氧基烷基、氰基和芳氧基的群；而R8和R9独立地选自氢、羟基、卤素、低烷氧基、酰基、羟基烷基、烷氧基烷基、羟基羰基、烷基、烷氧基羧酸酯、酰氧基烷基、氰基和芳氧基的群，或者R8和R9一起组成碳环或杂环结构，或者R8或R9与R6或R7一起组成与五环D环融合的碳环或杂环结构。
• Process for preparation of 9,11-epoxy steroids and intermediates useful therein
  申请人：——

  公开号：US20020042507A1

  公开（公告）日：2002-04-11

  Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula I 1 wherein: —A—A— represents the group —CHR 4 —CHR 5 — or —CR 4 ═CR 5 — R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halo, hydroxy, lower alkyl, lower alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, cyano, aryloxy, R 1 represents an alpha-oriented lower alkoxycarbonyl or hydroxyalkyl radical, —B—B— represents the group —CHR 6 —CHR 7 — or an alpha- or beta-oriented group: 2 where R 6 and R 7 are independently selected from the group consisting of hydrogen, halo, lower alkoxy, acyl, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, alkyl, alkoxycarbonyl, acyloxyalkyl, cyano, aryloxy, and R 8 and R 9 are independently selected from the group consisting of hydrogen, halo, lower alkoxy, acyl, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, alkyl, alkoxycarbonyl, acyloxyalkyl, cyano, aryloxy, or R 8 and R 9 together comprise a carbocyclic or heterocyclic ring structure, or R 8 or R 9 together with R 6 or R 7 comprise a carbocyclic or heterocyclic ring structure fused to the pentacyclic D ring.

  提供了多种新颖的反应方案、新颖的工艺步骤和新颖的中间体，用于合成环氧甾酮和其他I类化合物，其中：—A—A—代表基团—CHR4—CHR5—或—CR4═CR5—R3，R4和R5分别选自氢、卤素、羟基、低级烷基、低级烷氧基、羟基烷基、烷氧基烷基、羟基羧基、氰基、芳氧基，R1代表α定向的低级烷氧羰基或羟基烷基基团，—B—B—代表基团—CHR6—CHR7—或α-或β-定向的基团：2其中，R6和R7分别选自氢、卤素、低级烷氧基、酰基、羟基烷基、烷氧基烷基、羟基羧基、烷基、烷氧基羰基、酰氧基烷基、氰基、芳氧基，R8和R9分别选自氢、卤素、低级烷氧基、酰基、羟基烷基、烷氧基烷基、羟基羧基、烷基、烷氧基羰基、酰氧基烷基、氰基、芳氧基，或者R8和R9一起构成一个碳环或杂环结构，或者R8或R9与R6或R7一起构成一个与五环D融合的碳环或杂环结构。
• Process for the preparation of 9, 11 epoxy steroids
  申请人：Wieczorek J. Joseph

  公开号：US20050272927A1

  公开（公告）日：2005-12-08

  Processes are described for epoxidation reactions. In particular, the process comprises the conversion of a steroid substrate having an olefinic unsaturation in the steroid nucleus to a structure comprising a 9,11-epoxy substituent by reaction of the substrate with a peroxide compound in the presence of a peroxide activator. The epoxidation processes described are conducted at relatively low hydrogen peroxide to steroid substrate ratio. Several optional process modifications are described.

  本文介绍了环氧化反应的工艺。具体而言，该工艺包括在过氧化物活化剂存在的情况下，通过底物与过氧化物化合物的反应，将甾体底物转化为包含 9，11-环氧取代基的结构，该结构在甾体核中具有烯烃不饱和度。所述环氧化工艺是在过氧化氢与类固醇底物比率相对较低的条件下进行的。此外，还介绍了几种可选的工艺改良方法。
• 6 beta.7 beta; 15.16-Dimethylen-1.4-androstadien-3-one, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0019690B1

  公开（公告）日：1982-04-21
• Verfahren zur Herstellung von 3-(delta4-3ketosteroid-17alpha-yl)-propion-säurelactonen
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0117507B1

  公开（公告）日：1987-11-11